Enanta Pharmaceuticals
ENTA
133 hedge funds and large institutions have $438M invested in Enanta Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 60 increasing their positions, 35 reducing their positions, and 28 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 35
18% more call options, than puts
Call options by funds: $39K | Put options by funds: $33K
0.77% more ownership
Funds ownership: 95.28% → 96.05% (+0.77%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 144 → 133 (-11)
36% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 28
46% less capital invested
Capital invested by funds: $805M → $438M (-$367M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$9.58M |
| 2 |
State Street
Boston,
Massachusetts
|
+$9.35M |
| 3 |
Morgan Stanley
New York
|
+$5.17M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.99M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$3.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
-$10.7M |
| 2 |
CC
Commodore Capital
New York
|
-$8.79M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.58M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$6.42M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$4.92M |
ENTA Hedge Fund Activity: Q2 2023 in Review
133 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q2 2023, worth a combined $438M — down 46% from $805M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of ENTA and 18 opened new positions — a net loss of 10 holders — while 35 trimmed existing stakes and 60 added.
The largest buyer was Farallon Capital Management, adding an estimated $9.58M. The largest seller was First Manhattan, exiting entirely with an estimated $10.7M sold.
- 133 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q2 2023, down from 144 in Q1 2023.
- Funds reported $438M of Enanta Pharmaceuticals stock for Q2 2023, down 46% quarter-over-quarter.
- 18 funds opened new Enanta Pharmaceuticals positions in Q2 2023 and 28 closed out, a net change of -10 holders.
- The largest Enanta Pharmaceuticals buyer in Q2 2023 was Farallon Capital Management, an estimated $9.58M added.
- The largest Enanta Pharmaceuticals seller in Q2 2023 was First Manhattan, an estimated $10.7M sold.
Based on aggregated 13F filings for Q2 2023.